Johnson & Johnson (NYSE:JNJ) is one of the biggest pharmaceutical companies in the world. 2024 has been a very important year for the firm as it has agreed to pay a whopping $700 million to settle ...

J&J’s JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the ...

Johnson & Johnson (JNJ 0.98%) is a healthcare giant that derives the majority of its growth from its pharmaceutical business. J&J boasts a large product lineup that includes immunology drugs ...

JNJ's acquisition of Abiomed increases the prospects of the company advancing innovation in both Medtech and the pharmaceutical business. Sales of JNJ's pharmaceuticals were highest in the nine ...

The global pharmaceutical industry could generate about ... Argus has a "buy" rating and $185 price target for JNJ stock, which closed at $157.47 on April 17. AbbVie is a global biopharmaceutical ...

Bristol-Myers Squibb Co. (NYSE: BMY) remains a solid pharmaceutical stock to own in the long term, offering an outstanding entry point with a reliable dividend. Johnson & Johnson (NYSE ...

Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump moving decisively toward imposing tariffs on the pharmaceutical industry. The administration’s ...

Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands ...

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both companies have a strong presence in immunology, oncology and ...